Valion Bio, Inc. Common Stock
Here’s whether Valion Bio, Inc. Common Stock (VBIO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: RSI 36 — healthy momentum range. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-18.75% over 10 days); 3-month momentum negative (-78.3%); rising volume on a downtrend (distribution, 2.85x avg). Currently 85.3% off its 52-week high. Score: -2/7.
VBIO is trading below its 200-day MA (—) — a key warning sign the longer-term trend is under pressure. An RSI of 35.6 sits in the neutral zone — momentum is neither stretched nor exhausted. With ~4 months of trading history, the return since first available bar is -81.1%. The current 85.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.